Lilly Acquires Kelonia Therapeutics to Boost CAR-T Cell Therapy Innovations
Eli Lilly and Company has announced a strategic acquisition of Kelonia Therapeutics, a biotechnology firm specializing in innovative gene delivery systems. This acquisition, valued at up to $7 billion, enhances Lilly’s capabilities in genetic medicine and cell therapy.
Lilly’s Acquisition Overview
The acquisition involves an upfront payment of $3.25 billion, with additional payments contingent upon meeting clinical, regulatory, and commercial milestones. The deal is expected to close in the latter half of 2026, pending regulatory approvals.
Kelonia’s Innovative Technology
Kelonia Therapeutics has pioneered a sophisticated in vivo gene placement system known as iGPS®. This technology employs engineered lentiviral particles for targeted delivery of CAR-T therapies directly to T-cells within the patient’s body. The goal is to simplify and enhance the effectiveness of CAR-T treatments.
Key Product: KLN-1010
Kelonia’s leading candidate, KLN-1010, is an in vivo CAR-T therapy designed to treat relapsed or refractory multiple myeloma. Currently in Phase 1 clinical trials, KLN-1010 aims to generate anti-B-cell maturation antigen (BCMA) CAR-T cells. Early clinical results reported at the 2025 American Society of Hematology Annual Meeting demonstrate its promising tolerability and potential effectiveness.
Implications for Cancer Treatment
This acquisition allows Lilly to broaden its research in the oncology sector. The iGPS platform could help reduce complexities associated with traditional CAR-T therapies, which often involve lengthy and expensive manufacturing processes.
Executive Insights
Jacob Van Naarden, President of Lilly Oncology, stated that the in vivo delivery system could transform cancer treatment by enabling more patients to access CAR-T therapies effectively. Kevin Friedman, CEO of Kelonia, emphasized the potential for their technology to extend beyond hematologic malignancies to other serious diseases.
Future Prospects
- Transaction value: Up to $7 billion
- Initial payment: $3.25 billion
- Closing date: Expected in the second half of 2026
- Current clinical status of KLN-1010: Phase 1 trials ongoing
This acquisition marks a significant evolution in Lilly’s approach to cancer therapies, positioning the company to innovate within the genetic medicine landscape and bringing hope to patients in need of new treatment options.
